ALNYLAM PHARMACEUTICALS, INC.

## Alnylam's Inaugural Coverage: RNAi Pioneer at $41B Market Cap with Significant Diagnostic Gap Opportunity

This marks the first observation in Origin's continuous coverage of Alnylam Pharmaceuticals (ALNY), with the stock trading at $254.07 and a $41B market cap as of September 29, 2026. The most analytically striking data point from recent transcript captures is Alnylam's own modeling estimate that approximately 80% of ATTR-CM (transthyretin amyloid cardiomyopathy) patients remain undiagnosed globally. This is not a peripheral footnote — it represents the core commercial thesis for ALNY's lead franchise. If that diagnostic gap closes even partially through improved screening infrastructure, the addressable patient population could expand dramatically beyond current revenue run rates.
The 10-K filing signals are dense with risk factor language, logging 90, 89, 88, 50, 40, 40, and 39 matches across distinct risk categories, alongside 39 strategic event signals. This volume of risk factor density warrants careful parsing in future observations — high match counts often correlate with either genuine operational complexity or deliberate disclosure conservatism, both of which matter for long-term holders. The unusual transcript mention of "Automotive" and "Sovereign & Government" alongside core healthcare topics suggests either a conference format artifact or an emerging business development narrative worth clarifying.
With 624 all-time AI queries on Origin and only 2 transcripts captured so far, the analytical foundation here is thin. Key items to watch: ONPATTRO and AMVUTTRA volume trends, ATTR-CM diagnosis rate data from cardiology conferences, and any partnership or licensing signals emerging from the "Platform & Ecosystem" discussion thread.